Showing results (1661-1670 of 1,873) with videos related to

Sort By:
Pageof 188
Science Advances|September 27, 2024
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancerHirokazu Taniguchi, Subhamoy Chakraborty, Nobuyuki Takahashi, et al.
Lupus Science & Medicine|May 18, 2026
Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnanciesAgnes Torell, Kerstin Andersson, Iva Gunnarsson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2026
Distinct Transcriptomic Profiles in ART-Treated People with HIV Are Associated with NF-κB-regulated Gene Expression and Inflammatory Cytokine SignaturesYingfan Wang, German G Gornalusse, Urja Bhatt, et al.
Cell Reports|December 3, 2015
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 SpeciesHongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, et al.
Open Forum Infectious Diseases|October 14, 2017
A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant EnterobacteriaceaeOryan Henig, Eric Cober, Sandra S Richter, et al.
Cancer Cell|August 13, 2021
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosisKosuke Tanaka, Helena A Yu, Shaoyuan Yang, et al.
The Lancet. Oncology|July 1, 2024
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trialSalomon Tendler, Mark P Dunphy, Matthew Agee, et al.
The Lancet. Rheumatology|January 24, 2024
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trialKristina Lend, Ronald F van Vollenhoven, Jon Lampa, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
Pageof 188